Wara Samar
2nd June 2025
€15M Boost for Hedera Dx to Democratize Cancer Testing in Europe
Swiss-based techbio company Hedera Dx has raised €15 million in Series A funding to accelerate its mission of making precision cancer care accessible to all patients, regardless of geography. The round was led by Vsquared Ventures, with new investor Tesi and existing backers including Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest also contributing.
Founded in 2021, Hedera Dx is taking a different approach to cancer diagnostics. Instead of relying on centralized labs, common in the U.S., the company has developed liquid biopsy solutions that allow hospital labs to perform sophisticated molecular diagnostics in-house. This model is particularly relevant for Europe and other regions where health systems operate differently.
Hedera’s blood-based testing is already active in 11 European countries. The platform enables clinicians to identify actionable genetic alterations in cancer patients, opening the door to targeted therapies that would otherwise be inaccessible due to logistical and financial barriers.
“At Hedera, we are building the infrastructure to make precision cancer care accessible to every patient and clinician — globally,” said Tommi Lehtonen, CEO and co-founder of Hedera Dx in a statement. “While there is a large number of personalized cancer treatments on the market, a very large part of patients still can’t access them. Our solutions empower hospital labs to perform sophisticated molecular diagnostics locally and cost efficiently.”
More Than Diagnostics: Real-World Data Meets AI
What sets Hedera Dx apart is not only its decentralised approach to molecular testing but also its growing capability in real-world data analytics. The company’s AI-native platform is designed to extract patient-centric insights from clinical data, supporting the development of the next generation of oncology treatments.
Dr. Lise Rechsteiner, General Partner at Vsquared Ventures, emphasised this dual impact: “Hedera Dx is addressing a critical gap in global oncology care. Hedera’s approach tackles the specific challenges of hospital in-house testing and results in more patients getting tested and more patients having access to targeted therapies. Hedera Dx’s combination of diagnostics and powerful real-world data capabilities positions them to become the definitive leader in precision oncology within healthcare systems outside the US.”
The funding will be used to scale commercial operations and continue building Hedera’s data infrastructure — a critical component for pharmaceutical companies seeking to develop and validate new cancer treatments with real-world evidence.
“We’re not only improving access to advanced cancer care for patients — we are creating an entirely new platform for real-world insights, driving access to life-saving precision oncology treatments and fueling the next wave of innovative cancer therapies,” added Dr. Christian Meisel, CMO and co-founder of Hedera Dx.
As cancer care continues to move toward personalization, Hedera Dx is positioning itself as a vital enabler for hospitals, and ultimately, for patients, throughout Europe and beyond.
Join the Conversation at MedTech Malta 2025
As Europe continues to invest in smarter, more accessible cancer diagnostics, such companies reflect the kind of innovation that will be in focus at MedTech Malta 2025, taking place from 12–14 November at the Mediterranean Conference Centre in Valletta. The event will gather global leaders in MedTech, biotech, and health innovation to explore real-world applications of cutting-edge solutions in healthcare. For those interested in sponsorship, speaking opportunities, or pitching their startup, reach out to the MedTech World team at [email protected].
